Mirum Pharmaceuticals, Inc.MIRMEarnings & Financial Report
Mirum Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with rare, debilitating liver diseases that have high unmet medical needs, serving both pediatric and adult patient groups across North America, Europe and other global regions.
MIRM Q4 FY2025 Key Financial Metrics
Revenue
$148.9M
Gross Profit
N/A
Operating Profit
$-4.6M
Net Profit
$-5.7M
Gross Margin
N/A
Operating Margin
-3.1%
Net Margin
-3.8%
YoY Growth
49.8%
EPS
$-0.10
Mirum Pharmaceuticals, Inc. Q4 FY2025 Financial Summary
Mirum Pharmaceuticals, Inc. reported revenue of $148.9M (up 49.8% YoY) for Q4 FY2025, with a net profit of $-5.7M (up 75.9% YoY) (-3.8% margin).
Key Financial Metrics
| Total Revenue | $148.9M |
|---|---|
| Net Profit | $-5.7M |
| Gross Margin | N/A |
| Operating Margin | -3.1% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Mirum Pharmaceuticals, Inc. Q4 FY2025 revenue of $148.9M breaks down across 2 segments, led by Livmarli at $106.4M (71.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Livmarli | $106.4M | 71.4% |
| Bile Acid Medicines | $42.5M | 28.6% |
Mirum Pharmaceuticals, Inc. Revenue by Segment — Quarterly Trend
Mirum Pharmaceuticals, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Livmarli and Bile Acid Medicines) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Livmarli | $106.4M | $92.2M | $88.2M | $73.2M |
| Bile Acid Medicines | $42.5M | $40.8M | $39.6M | $38.4M |
Mirum Pharmaceuticals, Inc. Annual Revenue by Year
Mirum Pharmaceuticals, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $521.3M).
Mirum Pharmaceuticals, Inc. Quarterly Revenue & Net Profit History
Mirum Pharmaceuticals, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $148.9M | +49.8% | $-5.7M | -3.8% |
| Q3 FY2025 | $133.0M | +47.2% | $2.9M | 2.2% |
| Q2 FY2025 | $127.8M | +64.1% | $-5.9M | -4.6% |
| Q1 FY2025 | $111.6M | +61.2% | $-14.7M | -13.2% |
| Q4 FY2024 | $99.4M | +42.9% | $-23.8M | -23.9% |
| Q3 FY2024 | $90.4M | +89.4% | $-14.2M | -15.8% |
| Q2 FY2024 | $77.9M | +107.7% | $-24.6M | -31.6% |
| Q1 FY2024 | $69.2M | +119.1% | $-25.3M | -36.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $69.2M | $77.9M | $90.4M | $99.4M | $111.6M | $127.8M | $133.0M | $148.9M |
| YoY Growth | 119.1% | 107.7% | 89.4% | 42.9% | 61.2% | 64.1% | 47.2% | 49.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $652.0M | $660.8M | $667.9M | $670.8M | $690.2M | $725.8M | $785.1M | $842.8M |
| Liabilities | $417.4M | $431.8M | $435.9M | $445.1M | $457.0M | $470.7M | $493.1M | $528.1M |
| Equity | $234.6M | $229.0M | $232.0M | $225.6M | $233.3M | $255.2M | $292.0M | $314.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $15.2M | $-3.8M | $4.0M | $-5.1M | $-2.0M | $12.0M | $39.7M | $6.1M |